首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Varicella zoster virus vaccines: potential complications and possible improvements
Authors:Benjamin Silver  Hua Zhu
Institution:Department of Microbiology, Biochemistry & Molecular Genetics, Rutgers - New Jersey Medical School, New Jersey 07103, USA
Abstract:Varicella zoster virus(VZV) is the causative agent of varicella(chicken pox) and herpes zoster(shingles). After primary infection, the virus remains latent in sensory ganglia, and reactivates upon weakening of the cellular immune system due to various conditions, erupting from sensory neurons and infecting the corresponding skin tissue. The current varicella vaccine(v-Oka) is highly attenuated in the skin, yet retains its neurovirulence and may reactivate and damage sensory neurons. The reactivation is sometimes associated with postherpetic neuralgia(PHN), a severe pain along the affected sensory nerves that can linger for years, even after the herpetic rash resolves. In addition to the older population that develops a secondary infection resulting in herpes zoster, childhood breakthrough herpes zoster affects a small population of vaccinated children. There is a great need for a neuro-attenuated vaccine that would prevent not only the varicella manifestation, but, more importantly, any establishment of latency, and therefore herpes zoster. The development of a genetically-defined live-attenuated VZV vaccine that prevents neuronal and latent infection, in addition to primary varicella, is imperative for eventual eradication of VZV, and, if fully understood, has vast implications for many related herpesviruses and other viruses with similar pathogenic mechanisms.
Keywords:varicella zoster virus  herpesvirus  vaccine  neurovirulence  neuro-attenuation  latency  latent infection  herpes zoster  shingles  chicken pox  ORF7
本文献已被 CNKI 维普 万方数据 SpringerLink 等数据库收录!
点击此处可从《中国病毒学》浏览原始摘要信息
点击此处可从《中国病毒学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号